![Ryan Saadi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ryan Saadi
No más puestos en curso
Fortuna: 96 M $ al 31/05/2024
Perfil
Ryan Saadi is the founder of Tevogen Bio, Inc. and Tevogen Bio Holdings, Inc. He held the title of Chairman & Chief Executive Officer at both companies.
Tevogen Bio, Inc. was founded in 2020, while Tevogen Bio Holdings, Inc. was founded in 2024.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
71.30% | 05/06/2024 | 118 446 582 ( 71.30% ) | 96 M $ | 31/05/2024 |
Cargos activos de Ryan Saadi
Empresas | Cargo | Inicio |
---|
Antiguos cargos conocidos de Ryan Saadi.
Empresas | Cargo | Fin |
---|---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Director Ejecutivo | - |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Tevogen Bio, Inc.
![]() Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Bolsa de valores
- Insiders
- Ryan Saadi